# **Screening Libraries**

# (Rac)-Atropine-d<sub>3</sub>

Cat. No.: HY-B1205S CAS No.: 1276197-36-4 Molecular Formula:  $\mathsf{C}_{17}\mathsf{H}_{20}\mathsf{D}_3\mathsf{NO}_3$ 

Molecular Weight: 292.39

mAChR; Endogenous Metabolite; Isotope-Labeled Compounds Target:

Pathway: GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease; Others

Storage: Powder -20°C 3 years

In solvent

4°C 2 years

-80°C 6 months -20°C 1 month

**Product** Data Sheet

# **SOLVENT & SOLUBILITY**

DMSO: 50 mg/mL (171.00 mM; Need ultrasonic) In Vitro

> Ethanol:  $\geq$  16 mg/mL (54.72 mM) PBS (pH 7.2) : ≥ 10 mg/mL (34.20 mM) DMSO : ≥ 10 mg/mL (34.20 mM) DMF:  $\geq 2 \text{ mg/mL } (6.84 \text{ mM})$

\* "≥" means soluble, but saturation unknown.

| Preparing<br>Stock Solutions | Solvent Mass<br>Concentration | 1 mg      | 5 mg       | 10 mg      |
|------------------------------|-------------------------------|-----------|------------|------------|
|                              | 1 mM                          | 3.4201 mL | 17.1004 mL | 34.2009 mL |
|                              | 5 mM                          | 0.6840 mL | 3.4201 mL  | 6.8402 mL  |
|                              | 10 mM                         | 0.3420 mL | 1.7100 mL  | 3.4201 mL  |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.25 mg/mL (4.28 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.25 mg/mL (4.28 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.25 mg/mL (4.28 mM); Clear solution

# **BIOLOGICAL ACTIVITY**

| Description | (Rac)-Atropine-d <sub>3</sub> is the deuterium labeled (Rac)-Atropine[1].  |  |
|-------------|--|--|
| In Vitro    | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as |  |

tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs $^{[1]}$ .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

# **REFERENCES**

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com